Ann: Quarterly Shareholder Update, page-4

It is certainly a way better ride at the moment compared to years ago. a nice list of milestones coming up, and all given clear prospective timelines for completion. And judging by progress to date they will make those timelines and update the market at that time clearly and concisely. Cant ask for much more than that. All I can say is it makes a nice change to be on an apparent uphill trajectory after the last 11 years. As I mentioned before the ending of genentech collab with no real effect on sp seems to speak volumes of current strength.

from report.
Upcoming milestones
Looking forward to what lies ahead, we have an exciting path both to and through the clinic. This
journey will include:
i) A final additional assessment of PYC’s lead drug’s ability to reverse a disease process
in human cells that have the target disease (Retinitis Pigmentosa) – known as a
‘phagocytosis assay’, this provides an assessment of whether our drug can restore the
diseased cells’ ability to rid themselves of toxic build up (anticipated at the end of Q1
2020);
ii) A ‘clinical trial on a benchtop’ with ‘optic cups’/’retinal organoids’ from patients likely
to be enrolled in our phase 1 study (anticipated at the end of Q1 2020); and
iii) Initiation of IND-enabling studies demonstrating the safety of the lead drug candidate
in larger animal species (anticipated to begin in Q2 2020).